Protective effect of theaflavins on homocysteine-induced injury in HUVEC cells in vitro

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 5, 2012, Pages 434-440

  Wang, Wenxiang ^a   Sun, Yan ^b   Liu, Jin ^a   Wang, Jieying ^a   Li, Yuchen ^a   Li, Hong ^a   Zhang, Wenchang ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b Center for Reproductive Medicine   (China)

Author keywords

comet assay; homocysteine; HUVECs; reactive oxygen species; theaflavins

Indexed keywords

ENDOTHELIN 1; GLUTATHIONE PEROXIDASE; HOMOCYSTEINE; MALONALDEHYDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SUPEROXIDE DISMUTASE; THEAFLAVIN;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL PROTECTION; CELL STRUCTURE; CELL VIABILITY; COMET ASSAY; DNA DAMAGE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID PEROXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM;

ANTIOXIDANTS; BIFLAVONOIDS; CATECHIN; CELL SURVIVAL; COMET ASSAY; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; HOMOCYSTEINE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; REACTIVE OXYGEN SPECIES;

EID: 84861093169     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318248aeb3     Document Type: Article

References (37)

1. Refsum H, Ueland PM, Nygård O, et al. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31-62.
2. Scholzen TE, Stander S, Riemann H, et al. Modulation of cutaneous inflammation by angiotensin-converting enzyme. J Immunol. 2003;170:3866-3873.
3. McDowell IF, Lang D. Homocysteine and endothelial dysfunction: a link with cardiovascular disease. J Nutr. 2000;130:369S-372S.
4. Postea O, Krotz F, Henger A, et al. Stereospecific and redox-sensitive increase in monocyte adhesion to endothelial cells by homocysteine. Arterioscler Thromb Vasc Biol. 2006;26:508-513.
5. Anderson JL, Muhlestein JB, Horne BD, et al. Plasma homocysteine predicts mortality independently of traditional risk factorsand C-reactive protein in patients with angiographically defined coronary artery disease. Circulation. 2000;102:1227-1232.
6. Yang CS, Wang X, Lu G, et al. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer. 2009;9:429-439.
7. Gardner EJ, Ruxton CHS, Leeds AR. Black tea-helpful or harmful? A review of the evidence. European Journal of Clinical Nutrition. 2007;61:3-18.
8. Woodward M, Tunstall-Pedoe H. Coffee and tea consumption in the Scottish Heart Health Study follow up: conflicting relations with coronary risk factors, coronary disease, and all cause mortality. J Epidemiol Community Health. 1999;53:481-487.
9. Rimm EB, Katan MB, Ascherio A, et al. Relation between intake of flavonoids and risk for coronary heart disease in male health professionals. Ann Intern Med. 1996;125:384-389.
10. Hamer M, Williams ED, Vuononvirta R, et al. Association between coffee consumption and markers of inflammation and cardiovascular function during mental stress. Journal of Hypertension. 2006;24:2191-2197.
11. de Mejia EG, Ramirez-Mares MV, Puangpraphant S. Bioactive components of tea: Cancer, inflammation and behavior. Brain Behav Immun. 2009;23:721-731.
12. Tice RR, Agurell E, Anderson D, et al. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen. 2000;35:206-221.
13. Singh NP, McCoy MT, Tice RR, et al. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988;175:184-189.
14. Olive PL, Durand RE, Banath JP, et al. Analysis of DNA damage in individual cells. Methods Cell Biol. 2001;64:235-249.
15. Misra HP, Fridovich I. The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem. 1972;247:3170-3175.
16. Rotruck JT, Pope AL, Ganther HE. Selenium: biochemical role as a component of glutathione peroxidase purification assay. Science. 1973;179:588-590.
17. Brenman JE, Chao DS, Xia H, et al. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell. 1995;82:743-752.
18. Beuge JA, Aust SD. Microsomal lipid peroxidation. Meth Enzymol. 1978;52:302-310.
19. Paschenko SV, Khramtsov VV, Skatchkov MP, et al. EPR and laser flash photolysis studies of the reaction of nitric oxide with water soluble NO trap Fe (II)-proline-dithiocarbamate complex. Biochem Biophys Res Commun. 1996;225:577-584.
20. Prasanna G, Dibas A, Tao W, et al. Regulation of endothelin-1 in human nonpigmented ciliary epithelial cells by tumor necrosis factor-alpha. Exp Eye Res. 1998;66:9-18.
21. Wierzbicki AS. Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res. 2007;4:143-150.
22. Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B (12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol. 2003;136:1136-1150.
23. Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993;91:308-318.
24. Mercie P, Garnier O, Lascoste L. Homocysteine-thiolactone induces caspaseindependent vascular endothelial cell death with apoptotic features. Apoptosis. 2000;5:403-411.
25. Jamaluddin MD, Chen I, Yang F. Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. Blood. 2007;110:3648-3655.
26. Lang D, Kredan MB, Moat SJ, et al. Homocysteine-induced inhibition of endothilium-dependent relaxation in rabbit aorta: role for superoxide anions. ArteriosclerThromb Vasc Biol. 2000;20:422-427.
27. Lee SJ, Kim KM, Namkoong S, et al. Nitric oxide inhibition of homocysteineinduced human endothelial cell apoptosis by down-regulation of p53-dependent noxa expression through the formation of S-nitrosohomocysteine. J Biol Chem. 2005;280:5781-5788.
28. Verhoef P, de Groot LC. Dietary determinants of plasma homocysteine concentrations. Semin Vasc Med. 2005;5:110-123.
29. Anonymous. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the rando-mized trials. Am J Clin Nutr. 2005;82:806-812.
30. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565-575.
31. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567-1577.
32. Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578-1588.
33. Balentine DA, Wiseman SA, Bouwens LCM. The chemistry of tea flavonoids. Crit Rev Food Sci Nutr. 1997;37:693-704.
34. Vita JA. Tea consumption and cardiovascular disease: effects on endothelial function. J Nutr. 2003;133:3293S-3297S.
35. Coyle CH, Philips BJ, Morrisroe SN, et al. Antioxidant effects of green tea and its polyphenols on bladder cells. Life Sci. 2008;83:12-18.
36. Duh PD, Yen GC, Yen WJ, et al. Effects of pu-erh tea on oxidative damage and nitric oxide scavenging. J Agric Food Chem. 2004;52:8169-8176.
37. Lentz SR, Sobey CG, Piegors DJ, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst (e) inemia. J Clin Inves. 1996;98:24-29.